Founded in 2004 by Stéphane Ragusa, PrediLife combines proven medical techniques (genetic testing, medical imagery, etc.) with mathematical models using a very large amount of statistical data to produce innovative predictive solutions that enable individuals to ascertain their own risk profile for serious diseases. The company markets its MammoRisk® personalised breast cancer screening system in Europe, providing women and medical practitioners with a tool to assess individual risk.
PrediLife (ticker code: ALPRE) was listed on 21 December 2018 through the admission to trading of 2,758,154 shares making up its capital, including 386,154 new shares issued as part of a Global Offering[1].
The offering price was set at €9.30 per share. Market capitalisation on the day of listing was around €25.7 million, and the operation raised a total of €3.6 million.
At the listing ceremony, Stéphane Ragusa, CEO of PrediLife, said: “We are proud to announce our successful listing today on Euronext Growth in Paris, with the arrival of new shareholders whom we would like to thank for their trust. We also want to thank the existing investors that have renewed their support. Funds raised will allow PrediLife to step up the commercial rollout of our MammoRisk® solution in France and on international markets.”
[1] The Global Offering was made up of a Public Offering that included an Open Price Offer (OPO) and a Global Placement with institutional investors in France and other countries.